Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake

Journal of Biomedical Materials Research - Part A

Volumn 78, Issue 3, 2006, Pages 620-628

  Vonarbourg, A ^a   Passirani, C ^a   Saulnier, P ^a   Simard, P ^b   Leroux, J C ^b   Benoit, J P ^a  

^a UNIVERSITÉ D'ANGERS   (France)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Complement; Lipid nanocapsules; Macrophage; Polyethylene glycol; Protein adsorption

Indexed keywords

COMPLEMENT; LIPID NANOCAPSULES; MACROPHAGE; PROTEIN ADSORPTION;

BIOMATERIALS; DIALYSIS; ELECTROPHORESIS; IMMUNOLOGY; NANOSTRUCTURED MATERIALS; POLYETHYLENE GLYCOLS;

LIPIDS;

LABRAFAC WL 1349; LIPID; LIPOID S75 3; MACROGOL; NANOCAPSULE; NANOPARTICLE; PEGYLATED LIPID NANOCAPSULE; PHOSPHATIDYLCHOLINE; SOLUTOL HS 15; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DENSITY; DIALYSIS; IMMUNE SYSTEM; IMMUNOELECTROPHORESIS; IN VITRO STUDY; LIPID TRANSPORT; MACROPHAGE; NONHUMAN; OPSONIZATION; PARTICLE SIZE; RAT; STEREOSPECIFICITY; SURFACE PROPERTY;

ANIMALS; CAPSULES; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; LIPIDS; MACROPHAGES; MICE; NANOTECHNOLOGY; POLYETHYLENE GLYCOLS;

EID: 33747415451     PISSN: 00219304     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.30711     Document Type: Article

References (38)

1. Stolnik S, Illum L, Davis S. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 1995;16:195-214.
2. Passirani C, Benoit JP. Complement activation by injectable colloidal drug carriers. In: Mahato RI, editor. Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids. New York: CRC; 2005. p 187-230.
3. Kinoshita T. Biology of complement: The overture. Immunol Today 1991;12:291-295.
4. Vittaz M, Bazile D, Spenlehauer G, Verrecchia T, Veillard M, Puisieux F, Labarre D. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials 1996;17:1575-1581.
5. Mosqueira VC, Legrand P, Gulik A, Bourdon O, Gref R, Labarre D, Barratt G. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 2001;22:2967-2979.
6. Ilium L, Jacobsen LO, Muller RH, Mak E, Davis SS. Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials 1987;8:113-117.
7. Moghimi SM, Muir IS, Ilium L, Davis SS, Kolb-Bachofen V. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta-Mol Cell Res 1993; 1179:157-165.
8. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003;42: 463-478.
9. Moghimi SM, Hunter AC. Capture of stealth nanoparticles by the body's defences. Crit Rev Ther Drug Carrier Syst 2001;18: 527-550.
10. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 2002;19:875-880.
11. Heurtault B, Saulnier P, Pech B, Venier-Julienne MC, Proust JE, Phan-Tan-Luu R, Benoit JP. The influence of lipid nanocapsule composition on their size distribution. Eur J Pharm Sci 2003; 18:55-61.
12. Dagar S, Sekosan M, Lee BS, Rubinstein I, Onyuksel H. VIP receptors as molecular targets of breast cancer: Implications for targeted imaging and drug delivery. J Control Release 2001;74: 129-134.
13. Kreuter J. Colloidal Drug Delivery Systems. New York: Marcel Dekker; 1994. 219 p.
14. Ceroni M, Camana C, Giardini G, Savoldi F, Fumagalli M. Evaluation of zymosan-induced complement activation by CH50 test. Farmaco [Prat] 1986;41:147-154.
15. Passirani C, Barratt G, Devissaguet JP, Labarre D. Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sci 1998;62:775-785.
16. Mayer MM. Experimental Immunochemistry. Springfield, IL: Thomas; 1961. 156 p.
17. Kazatchkine MD, Hauptmann G, Nydegger UE. Techniques du Compĺment. Paris: Inserm; 1986. p 22, 23.
18. Liu D, Song YK, Liu F. Antibody dependent, complement mediated liver uptake of liposomes containing GM1. Pharm Res 1995;12:1775-1780.
19. Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 1998;46:255-263.
20. Vonarbourg A, Saulnier P, Passirani C, Benoit JP. Electrokinetic properties of noncharged lipid nanocapsules: Influence of the dipolar distribution at the interface. Electrophoresis 2005;26: 2066-2075.
21. Szebeni J, Baranyi L, Savay S, Milosevits J, Bodo M, Bunger R, Alving CR. The interaction of liposomes with the complement system: In vitro and in vivo assays. Methods Enzymol 2003; 373:136-154.
22. Carreno MP, Maillet F, Labarre D, Jozefowicz M, Kazatchkine MD. Specific antibodies enhance Sephadex-induced activation of the alternative complement pathway in human serum. Biomaterials 1988;9:514-518.
23. Alving CR, Swartz GM Jr. Antibodies to cholesterol, cholesterol conjugates and liposomes: Implications for atherosclerosis and autoimmunity. Crit Rev Immunol 1991;10:441-453.
24. Bradley AJ, Devine DV. The complement system in liposome clearance: Can complement deposition be inhibited? Adv Drug Deliv Rev 1998;32:19-29.
25. Devine DV, Wong K, Serrano K, Chonn A, Cullis PR. Liposome-complement interactions in rat serum: Implications for liposome survival studies. Biochim Biophys Acta 1994;1191:43-51.
26. Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 1994;11:402-406.
27. Jeon SI, Lee JH, Andrade JD, De Gennes PG. Protein-surface interactions in the presence of polyethylene oxide I. Simplified theory. J. Colloid Interface Sci 1991;142:149-158.
28. Antonsen KP, Hoffman AS. Water structure of PEG solutions by diffrential calorimetry measurements. In: Harris JME, editor. Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications. New York: Plenum; 1992. p 15-27.
29. Torchilin VP, Papisov MI. Why do polyethylene glycol-coated liposomes circulate so long? J Liposome Res 1994;4:725-739.
30. Stolnik S, Daudali B, Arien A, Whetstone J, Heald CR, Garnett MC, Davis SS, Illum L. The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers. Biochim Biophys Acta 2001;1514:261-279.
31. Cahouet A, Denizot B, Hindre F, Passirani C, Heurtault B, Moreau M, Le Jeune J, Benoit J. Biodistribution of dual radio-labeled lipidic nanocapsules in the rat using scintigraphy and γ-counting. Int J Pharm 2002;242:367-371.
32. Juliano RL, Stamp D. Biochem Biophys Res Commun 1975;63: 651-654.
33. Papisov MI. Theoretical considerations of RES-avoiding liposomes: Molecular mechanics and chemistry of liposome interactions. Adv Drug Deliv Rev 1998;32:119-138.
34. Nagaoka S, Mori Y, Takiuchi H, Yokota K, Tanzawa H, Nishiumi S. Interactions between blood components and hydrogels with poly(oxyethylene) chains. In: Shalaby SW, Hoffman AS, Ratner BD, Horbett TE, editors. Polymers as Biomaterials. New York: Plenum; 1984. p 361-375.
35. Raschke WC, Baird S, Ralph P, Nakoinz I. Functional macrophage cell lines transformed by Abelson leukemia virus. Cell 1978;15:261-267.
36. Shibuya-Fujiwara N, Hirayama F, Ogata Y, Ikeda H, Ikebuchi K. Phagocytosis in vitro of polyethylene glycol-modified liposome-encapsulated hemoglobin by human peripheral blood monocytes plus macrophages through scavenger receptors. Life Sci 2001;70:291-300.
37. Goodrum KJ. Complement component C3 secretion by mouse macrophage-like cell lines. J Leukoc Biol 1987;41:295-301.
38. Hoarau D, Delmas P, David S, Roux E, Leroux JC. Novel long-circulating lipid nanocapsules. Pharm Res 2004;21:1783-1789.